3149 – OBESITY INDUCED INFLAMMATION EXACERBATES CLONAL HEMATOPOIESIS

Santhosh Kumar Pasupuleti,Baskar Ramdas,Sarah S. Burns,Lakshmi Reddy Palam,Rahul Kanumuri,Ramesh Kumar,Taruni Reddy Pandhiri,Utpal Dave,Nanda Kumar Yellapu,Xinyu Zhou,Chi Zhang,George E. Sandusky,Zhi Yu,Michael Honigberg,Alexander Bick,Gabriel K. Griffin,Abhishek Niroula,Benjamin L. Ebert,Pradeep Natarajan,Sophie Paczesny,Reuben Kapur
DOI: https://doi.org/10.1016/j.exphem.2023.06.256
IF: 3.249
2023-01-01
Experimental Hematology
Abstract:Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated pathologies. We analyzed exome sequencing and clinical data from 47,466 individuals with validated CHIP in UK Biobank. CHIP was present in 5.8% of the study population and was associated with a significant increase in waist-to-hip ratio (WHR). We also examined the association between baseline obesity measured as BMI (n=46,460), WHR (n=47,405) and the risk of developing future myeloid leukemia. The hazard ratio (HR) (95% confidence interval (CI)) incident of myeloid leukemia per 1-SD increase in BMI was 1.71 (1.23, 2.38) with a p-value of 1.31E-03, and that of WHR was assessed to be 1.59 (0.91, 2.79) with a p-value of 1.05E-01. Furthermore, mouse models of obesity and CHIP driven by heterozygosity of Tet2, Dnmt3a, Asxl1 and Jak2 resulted in exacerbated expansion of mutant HSC/Ps due in part to excessive inflammation. Our results show that obesity is highly associated with CHIP and a pro-inflammatory state can potentiate progression of CHIP to more significant hematologic neoplasia. Calcium channel blocker, nifedipine or SKF-96365, either alone or in combination with metformin, MCC950 or anakinra (IL-1 receptor antagonist), suppressed the growth of mutant CHIP cells and partially restored normal hematopoiesis. Targeting CHIP mutant cells with these drugs could be a potential therapeutic approach to treat CH and its associated abnormalities in obese individuals.
medicine, research & experimental,hematology
What problem does this paper attempt to address?